logo-loader
viewOrthocell Ltd

Orthocell publishes positive pre-clinical trial study for CelGro nerve repair

Orthocell Ltd (ASX:OCC) managing director Paul Anderson updates Proactive Investors on the company’s positive pre-clinical study results for CelGro nerve regenerative treatment.

The results validate claims that the technique can deliver higher quality nerve repair, compared to existing methods.

Results also showed the use of CelGro in rats restored nerve fibres to complete regeneration, with these being indistinguishable from normal nerve histology.

Quick facts: Orthocell Ltd

Price: 0.495 AUD

ASX:OCC
Market: ASX
Market Cap: $91.26 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Bulls, Bears & Brokers: Alto Capital’s Tony Locantro on Nyrada IPO and small...

Alto Capital investment manager and stock market commentator Tony Locantro updates Proactive on this week's listing of Nyrada Inc (ASX:NYR), a spin-off of Noxopharm Ltd’s (ASX:NOX). He discusses the reasons for the spin-off, including some of the recent and expected trading patterns. Locantro...

2 days, 1 hour ago

2 min read